TTA Alerts Return: Teladoc’s investor fight, Walgreens’ and 23andMe’s take-privates on, layoffs at UHG and HHS bite, Transcarent, VCs meet Sherlock Holmes, much more!

February 27, 2025 | by

 

We’re back and in a new format! What’s hot: Sycamore taking Walgreens private is on, Wojcicki may finally take 23andMe private, Teladoc fights back against a short seller investor, Veradigm in the body board shop, UHG’s and HHS’ big layoffs, and Deep Dives into Transcarent and the no-way-pristine VC Business.

These just in: drug compounders sue FDA over semaglutide scarcity removal; Sycamore’s Walgreens buy plans begin to show (Prepared to move?)

23andMe gets a $74.7M offer from Wojcicki and New Mountain Capital–this time for real? (What’s the alternative?)

Short takes: a guide to HIMSS25, Google Watch clears loss of pulse detection, OpenEvidence’s AI-powered $75M raise, Retrieve Medical to buy Cúratus, HerMD women’s health closes (What will HIMSS be like?)

This Just In: Walgreens settles PWNHealth/Everly Health arbitration award for $595 million, reduced from $1 billion (Making the way ready?)

Has VA ‘done its homework’ and ready to restart the Oracle Cerner EHR Modernization? Timing and costs still not set. And 1,400 ‘non-mission critical employees fired. (updated 27 Feb) (VA and Cerner meet the new Committee)

Teladoc responds to Blue Orca’s report on BetterHelp’s AI ‘therapy’ (updated) (Rebutting allegations by Blue Orca)

News roundup: DOJ investigating UHG on Medicare Advantage billing upcoding; Teladoc’s BetterHelp therapists using AI?–a short seller alleges; Hims whacked by FDA ending compounded GLP-1s (updated); some fired FDA staffers in CDRH reinstated (Teladoc’s short seller alleges AI use, GLP-1 compounding pulled by FDA)

Veradigm changes up, expands its board in agreement with major investor; adds directors, chair to step down (Another shareholder step-in and cleanup on Aisle 5)

The wrapup line on ViVE (Now the premier digital health meeting venue)

Breaking: Will telehealth extensions survive past 31 March? ATA addresses rumors. (Still being worked on)

Last week:

News roundup 21 Feb: UHG offers buyouts to 30K before layoffs; more inside the Transcarent-Accolade deal; Hims acquires NJ testing company; layoffs bite inside HHS; in fundings, Vitalchat gains $6M, Frontera’s seeds at $32M, Harrison.ai $112M (AU), Abridge’s $250M (Overhiring, AI, offshoring hit UHG employees)

“It’s alive!” Walgreens’ deal with Sycamore Partners may be back on the table: report (Looks like it is!)

Two Must Reads: What’s Glen Tullman’s real game with Transcarent and the Accolade buy? Plus an extra helping on the VC ‘mafia’ and Hippocratic AI. (Real ‘Sherlocking’ investigative reporting)

* * *
Advertise on Telehealth and Telecare Aware
Support not only a publication but also a well-informed international community.

Contact Editor Donna for more information.

Help Spread the News

Please tell your colleagues about this free news service and, if you have relevant information to share with the rest of the world, please let me know!

Donna Cusano, Editor In Chief
donna.cusano@telecareaware.com

Telehealth & Telecare Aware – covering news on latest developments in telecare, telehealth and eHealth, worldwide.

These just in: drug compounders sue FDA over semaglutide scarcity removal; Sycamore’s Walgreens buy plans begin to show

February 27, 2025 | by

What the telehealth prescribers can’t do, the compounders are. A major drug compounder association, the Outsourcing Facilities Association, along with member North American Custom Laboratories, LLC, both based in Texas, filed suit yesterday (24 February) against the FDA to vacate the final action removing semaglutide, the active ingredient in GLP-1 drugs, from the shortage list. The FDA announced that it was being removed from the shortage list effective April-May, after months of compounders legally creating semaglutide-based weight loss drugs as permitted during the shortage. This was certainly good news for Novo Nordisk, the pharmaceutical company that developed and markets Ozempic and Wegovy [TTA 25 Feb].

The compounding was a boon for telehealth providers such as Hims and Hers, Ro, 23andMe (Lemonaid), Future Health, Weight Watchers, Lark, and many others. It allowed them to customize injectable formulations for customers on weight loss programs at a far lower cost than standard branded products. The FDA allows this only during times of shortage (compounded by Section 503A pharmacies and Section 503B outsourcing facilities as “essential copies” of FDA-approved drugs). Exceptions are also made if the standard drug is in some way inappropriate for the patient who then medically requires a customized version, e.g. with adjusted dosage, method of dosing, or added/deleted ingredients, but these are not ‘mass’ circumstances or situations. 

Among the grounds presented in the suit against the FDA are that the shortage is still going on with delays in prescription filling, leading to patient harm; that FDA’s delisting was arbitrary without the required notice with public comment nor was it published in the Federal Register; and that it is ‘arbitrary and capricious’. Novo Nordisk has admitted publicly that supply constraints could still exists. 

Continued ‘customization’ is vital to telehealth prescribers’ revenue, while branding is vital to the pharmaceutical developers undercut by compounding. In 2024, Hims alone earned $225 million in revenue from compounded semaglutide and other GLP-1 type drugs. Both Novo Nordisk and Lilly (Zepbound) have pushed back on the compounders on safety and risk, along with lower prices in new delivery types such as vials versus autoinjectors.

The suit was filed in the US District Court for the Northern District of Texas. Biopharma Dive

More intriguing details if Sycamore Partners takes Walgreens Boots Alliance private. Financial Times reported via Reuters that according to the usual “people familiar with the matter”, Sycamore’s plan is to separate WBA into three parts, like Gaul: US retail pharmacy, Boots UK, and US Healthcare (VillageMD, CareCentrix, and Shields Health Solutions). They would have distinct capital structures. There’s minimal information beyond that. Sycamore is not expected to have difficulty financing the take-private, and WBA chairman Stefano Pessina is expected to have an ownership stake. The news drove WBA shares up today about 5% and 10% in the last five days. But the news seems to be moving along. VillageMD’s on the market is assumed but it is not certain any sale would complete in time. Crain’s Chicago Business

23andMe gets a $74.7M offer from Wojcicki and New Mountain Capital–this time for real?

February 27, 2025 | by | 2 Comments

If at first you don’t succeed, make another take-private offer, as the company is sinking. Anne Wojcicki, CEO of the terminally beleaguered 23andMe, has with little fanfare placed on the table a take-private offer for $2.53 per share, or $74.7 million, a small premium above their Friday close on Nasdaq CM at $2.42. (Wednesday’s close was $2.23.) With a market cap today of $65 million, it is a far cry from their post-SPAC days in 2021 where their valuation hit a peak of $4.8 billion by October. The news was revealed in their filing of a Schedule 13D with the Securities and Exchange Commission.

Ms. Wojcicki, or more exactly the Anne Wojcicki Revocable Trust, is backed in this take-private transaction by New Mountain Capital, with her legal advice from heavyweight law firm Skadden Arps Slate Meagher & Flom LLP. New Mountain Capital is being advised by Ropes & Gray LLP. Dechert LLP is reportedly on the company’s side although in January Goodwin Procter LLP was listed.

This is a far cry from her seemingly off-the-cuff offer of $0.40 on 31 July to the previous board’s Special Committee, which this Editor estimates at a $11-12 million offer. The 23andMe seven-person board rejected it a few days later, then departed in frustration on 17 September 2024. They were replaced by a three-person board–plus Ms. Wojcicki, the controlling shareholder. After their 28 January Q3 report that simply confirmed their sinking liquidity and revenue despite shedding/closing lines of business, the new Special Committee, consisting of the three outside directors, opened up 23andMe to ‘strategic alternatives’ on 31 January. 

The consumer/research genetics company’s cash on hand is an anemic $79.4 million as of 31 December–barely above, and likely currently below the $74.7 million Wojcicki/NMC offer. There is nothing left to sell other than Lemonaid [TTA 22 Jan]–but why no one is stepping up to buy a company with a foothold in telehealth remedies including GLP-1 drugs, even with FDA’s change away from compounded drugs, is a mystery

Assume this is a best offer? Whether this non-binding proposal will be countered by others is not known, but a safe assumption is that this will be the only one on the table. Ms. Wojcicki has effective majority control, confirmed in the Schedule 13D filing as 20% of Class A common stock and 69.4% of Class B common stock. Reportedly this gives her 49.99% of the voting power. Both Ms. Wojcicki and New Mountain are offering secured debt financing to fund 23andMe’s operations through the transaction’s closing, As a result, other offers are not likely in this Editor’s estimation.

No timing is reported or comment available from 23andMe.   CNBC, Lawyer Monthly

Short takes: a guide to HIMSS25, Google Watch clears loss of pulse detection, OpenEvidence’s AI-powered $75M raise, Retrieve Medical to buy Cúratus, HerMD women’s health closes

February 27, 2025 | by

Going to HIMSS25 in Las Vegas next week (3-7 March)? The huge annual conference, now run by Informa Markets, still features the HIMSS organization and head Hal Wolf front and center. But most go there not so much for the information sessions but for the networking, greeting, demo-ing ones’s wares, and meetings meetings meetings. (And Las Vegas) Both new are the AI Pavilion and the Interoperability Pavilion. Expect about 30 to 35,000 attendees across three venues in Vegas and if you want to really cover it, wear comfortable shoes. Strategize your show on the airplane or this weekend, and take some time to visit the smaller exhibitors. The always on top of it HIStalk provides a short guide here, though this Editor doesn’t know whether any of their team will attend or they will have some commentary from readers, so check back with them. (No, I won’t be there.) Healthcare Finance News, part of HIMSS Media, has a month-old preview video with editor Mike Miliard and Hal Wolf. To be sure, HIMSS Media publications will be covering nearly everything there except the blackjack. In stereo.

Google Watch’s loss of pulse detection clears FDA, finally. The Pixel Watch 3’s loss of pulse feature, launched last year, had clearance in 14 European countries but the FDA clearance opens the door for its use in the US. Loss of pulse (your heart stops beating) or sensing a pulse will show an “I’m OK” prompt. No answer or activity will trigger an emergency alert and call emergency services. It will be activated for US owners sometime in March. Users have to enable it from the Pixel Watch app on your phone > Safety & emergency. It is similar to Google’s existing Car Crash and Fall Detection features. 9to5 Google, Mobihealthnews

OpenEvidence’s $75 million Series A boosts it to $1 billion valuation. The medical information platform is an aggregator for medical information and research. Its LLM AI chatbot is trained on clinical information sources that include 45 years of the New England Journal of Medicine, licensing agreements with peer-reviewed medical journals, and the Mayo Clinic, from which it was spun off.  The company claims use in 10,000 US care centers.  It is also free with unlimited use by healthcare professionals, with the app available on Apple’s and Google’s stores. The Series A was funded by Sequoia Capital. The new funds will be used for strategic content partnerships, to train next-generation LLMs, and grow its team of scientists. With total funding over $100 million, its valuation is now $1 billion. Mobihealthnews, CNBC

Retrieve Medical plans to acquire Cúratus LLC.  Both seem to be bootstrapped data companies, with Retrieve analyzing patient data from multiple sources using advanced natural language processing (NLP) in its Retrieve Dx product for providers to understand complex clinical histories and diagnose chronic conditions. It integrates with major EHRs. Cúratus provides to health plans and provider groups provider data management, and governance for the Medicare Advantage, Medicaid, and commercial payer markets through its ProviderLenz platform. The letter of intent does not disclose offer price, timing, headquartering, or management transitions. Release

Women’s health is supposed to be hot–but here’s another closure against the trend. HerMD, a Cincinnati-based comprehensive practice focused on women’s health that utilized both in-office visits and in-person assessments, coupled with virtual tools, is closing for unclear reasons, other than “ongoing challenges in health care”, perhaps code for running out of money. Their closure on 21 March was disclosed 24 February in an email to patients. The information is not on the website.

Interestingly, it raised a not-inconsiderable $36 million in total funding from its founding in 2015, with investors including Jazz Venture Partners, B-Flexion, and Amboy Street Ventures, expanding beyond Cincinnati to Indiana, Tennessee, and New Jersey. Why their attractive concept, which included longer form visits and aesthetics, did not gain traction is a mystery to this Editor. Perhaps they should have branched out into that other blistering trend, GLP-1 drugs for weight loss. CincyInno

This Just In: Walgreens settles PWNHealth/Everly Health arbitration award for $595 million, reduced from $1 billion

February 26, 2025 | by

A golden bird in the hand for PWN/Everly–and presaging something else for Walgreens? Walgreens has decided to settle with PWN/Everly the latter’s recently upheld near-$1 billion arbitration award for $595 million, about 60%. This amount is payable to Everly in a breathtaking two business days.

The arbitration between PWN/Everly and Walgreens charged Walgreens with breach of contract on their Covid-19 testing services agreement, adding in additional violations of the Latham Act on trademarks and more. The arbitrator’s award of $987 million last March was affirmed by the US District Court for the District of Delaware on 11 February. Walgreens declared it would appeal but stated in their SEC filing that any resolution might take up to two years. More details: TTA 12 Feb

Was this a ‘Deal Deal’ as a prelude to a more significant endgame for Walgreens? For this Editor strictly speculating, Walgreens not appealing but settling this quickly, agreeing to pay a reduced amount in record time, may point to something larger. If coupled with the speculated revival of the Sycamore Partners buyout deal [TTA 19 Feb], if Walgreens is actively in sale mode, they want to be as attractive as possible. That means taking off the table ongoing lawsuits and pending settlements that are future obligations–presenting the cleanest picture possible of and reducing their Mound of Misery. Where they can, like with Everly, it’s settling for less now, versus dragging out an appeal for two years that will be more costly to litigate, for example in legal fees and award interest, if almost certainly upheld again. These become future obligations for a buyer and make for more unattractiveness. It also follows on VillageMD/CityMD’s recent settlements with New York State and the Department of Justice [TTA 12 Feb] and state-level opioid settlements, though in January the DOJ filed a civil lawsuit against Walgreens on opioids and other meds violating the Controlled Substances Act [TTA 24 Jan] . Reuters, Crain’s Chicago Business

Has VA ‘done its homework’ and ready to restart the Oracle Cerner EHR Modernization? Timing and costs still not set. And 1,400 ‘non-mission critical employees fired. (updated 27 Feb)

February 26, 2025 | by

New Congress, new hearings of the House Committee on Veterans’ Affairs Subcommittee on Technology Modernization on the EHRM, and a new chairman. Rep. Tom Barrett’s  (R-Mich. 7th CD) opening remarks for the 24 February were more than an introduction of him as a new Congressman and subcommittee chairman. He is a 22-year Army veteran, a patient of the Battle Creek MI Medical Center, and had used the Montgomery GI Bill to pay for his college education. What he was less than sanguine about was the Oracle Cerner EHR–the problems, the budget, the timing for the restart, and whether all medical centers can be cut over by 2028, the contract’s end.

It’s seven years into VA’s original 10-year contract with Cerner, then Oracle. The implementation is in less than 4% of VA’s medical centers–only six including the joint MHS-VA Lovell Medical Center in Chicago. The contract in May 2023 was modified to five years of annual renewals expiring in May 2028. Rep. Barrett questions whether all the problems have been fixed or on the way to be fixed in order to meet the previous VA Secretary, Denis McDonough’s pronouncement last year that the VA would restart the Oracle implementation in spring 2026 [TTA 18 Dec 2024–the original statement was within FY 2025].

Two more open questions are cost and timing. Congress has no current schedule, nor a cost estimate for the entire project. The last independent cost estimate is three years old and $32.7 billion–more than double the original estimate of $16 billion.

The hearing confirmed that the homework is not done yet and not ready to be turned in, in Rep. Barrett’s words. During the hearing, the committee pressed VA about both those issues. The Government Accountability Office (GAO)’s Information Technology and Cybersecurity Director Carol Harris cited another estimate above $50 billion, which was contested by Oracle Health’s EVP, Seema Verma (former CMS Administrator during Trump 45), who believes that with the progress made during the hiatus, that the costs would be less and the Oracle EHR is much improved from the near-disastrous five original implementations. But Neil Evans, the acting program executive director of the EHRM Office, stated that the implementation would not be completed by the contract end in May 2028. Moreover, the EHRM Office still has to develop a detailed integrated master schedule and updated life cycle cost estimate. Both were emphasized as needed by acting VA Inspector General David Case. A hearing with few revelations, other than VA and Oracle need to get a move on. House Committee press release, NextGov/FCW  The full two-hour hearing is on YouTube here.  Hat tip to HIStalk.

Updated 27 Feb: Additional information from the GAO, EHRM Office and Oracle Health’s Seema Verma testimony from Healthcare IT News 27 Feb:

  • GAO (Carol Harris): The VA still has to address over 1,800 requested configuration changes, along with the cost and schedule and the continued user dissatisfaction with the system. Improvements: trouble tickets resolution timeliness thresholds were met since the implementation of financial consequences in September 2023, and that many but not all patient safety and pharmacy issues have been closed–and should be before further deployments.
  • EHRM Office (Neil Evans): A series of complex projects are moving forward, dubbed “Big Rocks”. These include standardizing user roles, improving new EHR user training for new users and addressing coordination between clinicians and pharmacists.
  • Oracle Health (Seema Verma): Presented plans to scale the EHR to the remaining 164 (sic) locations. She pushed for faster implementations, stating that the current pace is unacceptable. They are investing into automating implementations that would reduce manual testing efforts, user onboarding and training. She recommended to VA that they use “web-based tools” to gather site-specific information faster. On “Big Rocks” projects, Oracle worked with VA on pharmacy, referrals, Quick Orders, and other aspects of the EHR. 

And what about accessibility? Last June, Laurette Santos, a visually impaired clinical social worker at VA’s White City, Oregon, facility, sued VA in the DC Federal Court on the Oracle EHR violating accessibility standards. These have been part of every Federal contract since the Rehabilitation Act of 1973, specifically in Section 508. She has standing in court as a VA Visual Impairment Services Team (VIST) Coordinator since 2019 and user of the Job Access With Speech (JAWS) screen reader application within VistA. There is no Oracle equivalent.  TTA 8 July 2024

Updated 26 Feb: VA has not been exempt from the firings of probationary employees. 1,000 were terminated on 13 February followed by another 1,400 this week. They were categorized in the VA release as “non-mission critical includ(ing) DEI-related positions, among other roles” and “bargaining-unit probationary employees who have served less than a year in a competitive service appointment or who have served less than two years in an excepted service appointment.” The estimated savings of $83 million annually will be redirected towards care and services for VA beneficiaries. What’s often not mentioned in press coverage is that there are 40,000 probationary employees across VA, the vast majority are in mission-critical positions such as benefits and services for VA beneficiaries–and that VA has open 300,000 mission-critical positions exempt from hiring freezes. Another buffer is that a Senior Executive Service (SES) or SES-equivalent leader in a dismissed employee’s chain of command can request that the employee be exempted from removal and that those in the deferred resignation program are also exempt. The Hill is notable for what is included and excluded.

Teladoc responds to Blue Orca’s report on BetterHelp’s AI ‘therapy’ (updated)

February 25, 2025 | by | 2 Comments

Teladoc formally responds to the Blue Orca Capital research report [TTA 25 Feb]. Their letter (PDF) via its legal counsel (King & Spalding) yesterday refutes Blue Orca’s allegations in a report on their stock (TDOC) that a “meaningful” number of BetterHelp patients are receiving AI therapy from therapists in the form of text/asynchronous and live messages, calling them “vague and unsubstantiated”.

The policy stated by Teladoc, quoted directly from this letter (Editor’s notes):

  • BetterHelp expressly prohibits therapists from disclosing any member personal or health information to third-party AI. (Editor’s emphasis)
  • BetterHelp has a Trust and Safety team dedicated to the detection and prevention of non-compliant use of AI and, if anything, has structured its platform (and its incentives to therapists) to promote live video calls over asynchronous messaging. (Another point made by Blue Orca)
  • BetterHelp’s Privacy Policy provides further disclosures to members concerning its AI practices. (The Privacy Policy is at the end of Section 1 Data Collection and Processing, and is specific as to AI being used for ‘manual, repetitive tasks’ in processing and to “help therapists manage and document sessions more effectively”.)

Readers will note that this Editor called Blue Orca’s statements in its report about AI therapy “allegations”. I also noted that Blue Orca was a short seller. I later clarified what a ‘short seller’ is and that short sellers profit when the stock goes down. Short sellers are also prohibited by securities law from spreading false information about a stock for the purposes of profiting from its decline (Rule 10b-5 under the Securities Exchange Act of 1934.)

The Teladoc counsel letter to Blue Orca Capital addresses other allegations in the Blue Orca report about their changes in reporting practices in FY 2022 that supposedly inflated Teladoc’s profitability. These are outside the scope of both articles and will not be commented on here.

Disclosure: Teladoc reached out to this Editor, supplying information about their response including the King & Spalding letter.

This Editor hopes, and would like to see confirmation, that any BetterHelp therapist using third-party AI to respond to patients in providing direct therapy, versus Teladoc/BetterHelp supplied management tools, customer service information, or security tools, is disciplined and released. The integrity, privacy, and security of a telementalhealth platform is essential to its operation and the confidence of its patients–and should be publicly confirmed.

Update: In response to this article, a spokesperson from Teladoc Health further elaborated:

“To be clear, BetterHelp expressly prohibits therapists from disclosing any member personal or health information to third-party AI. BetterHelp has clear, rapid processes for members to report negative experiences, switch therapists, and cancel memberships, when requested. If a therapist is found to be practicing in an unethical manner, they are investigated and terminated from the platform. The overwhelming majority of members stay with their matched therapist, even though they are free to switch their therapist at any time.” 

News roundup: DOJ investigating UHG on Medicare Advantage billing upcoding; Teladoc’s BetterHelp therapists using AI?–a short seller alleges; Hims whacked by FDA ending compounded GLP-1s (updated); some fired FDA staffers in CDRH reinstated

February 25, 2025 | by

UHG’s annus horribilis gets more horribilis. News broke on Friday 21 February via the Wall Street Journal (paywalled) that UnitedHealth Group is reportedly under investigation by the US Department of Justice–again.  The DOJ is looking at UHG’s billing practices for members covered by UnitedHealthcare Medicare Advantage (MA) plans on diagnoses that were made to generate extra payments, a practice known in the industry as upcoding. This also involves the many practices that UHG owns or has relationships through Optum, about 10% of primary care practices. These practices are receiving visits from DOJ investigators, certainly something that would strike some fear into any doctor’s or practice manager’s heart. 

The WSJ reported that two providers cited in their article provided documentation, while another person said that the Department of Health and Human Services’ Office of Inspector General (HHS-OIG) is involved in the probe.

It’s a real Mound of Misery for UHG.

  • MA plans and their set rates for additional benefits not covered under original Medicare have been under HHS/CMS scrutiny in the past year, and health plans have been running higher costs than anticipated as covered patients have returned back to care.
  • UHG’s OptumRx unit last year was reported as under investigation on antitrust grounds.
  • Optum’s Change Healthcare (contested by DOJ but approved) is still recovering from an unprecedented hacking and ransomwaring, with the huge expense of restoring systems plus notification and providing a reported 100 million with free credit monitoring services.
  • The proposed $3.3 billion deal with Amedisys for home care continues to be delayed by the DOJ antitrust suit.
  • Their UnitedHealthcare president was assassinated in New York, and his (alleged) killer is starting his trial here, a spectacle which will go into the summer. But the issue that supposedly tipped off the murder–claim denials and denials of care due to policies and the use of AI, isn’t going away–jumping in the fray is megainvestor Bill Ackman.

While Federal involvement with health plans comes with the territory, the adversarial relationship with DOJ far exceeds the norm. The share price reflects it, having cracked 26% in the past six months. Those accepting the 30,000 buyouts on offer may be grateful if they take them. CNBC, FierceHealthcare

Another backwash from the use of AI? Teladoc is receiving some bad publicity it can ill afford. There are allegations of their therapists using AI-drafted responses with patients–and this apparently is becoming more frequent. It’s been percolating on social media boards such as Reddit (see example here) for some time. The latest is a report from a short seller* of Teladoc, Blue Orca Capital, that alleges that BetterHelp therapists not only use ChatGPT for text responses outside of live sessions (messaging), but also during live chat sessions. This goes against Teladoc’s own stated policy against AI therapy as ‘dehumanizing’  in a lengthy blog post ranging from social media to job loss as a result as AI. Blue Orca includes first hand information from two BetterHelp patients, an allegation from a competitor that BetterHelp doesn’t care, and that therapists are actually incentivized on the word length of responses they give to a patient, overloading their schedule, and being available 24/7 to patients paying a reported $400/month. Given BetterHelp’s prominence in Teladoc’s earnings–according to them “accounting for 40% of the Company’s revenues and adjusted EBITDA since FY21”, adding in their other financial factors, their dim view is jarring if you like or own TDOC.  Developing. Hat tip to HIStalk 2/24/25

*Editor’s note: Blue Orca Capital, as a short seller, profits when a stock goes down. Blue Orca has a short position in TDOC. So our Readers should take their position into account. Short sellers are also prohibited by securities law from spreading false information about a stock for the purposes of profiting from its decline (Rule 10b-5 under the Securities Exchange Act of 1934.)

The Feds giveth and taketh away Hims’ weight loss business. Updated information. Friday’s good news was that FDA has reclassified the shortage of semaglutide, the active ingredient in GLP-1 drugs, as ‘resolved’, meaning It’s Over and it’s easier to get your Wegovy, Ozempic, Zepbound, etc. prescription. The bad news is that online prescribers that were authorized by FDA to use less expensive compounding to approximate or customize the branded versions of these drugs for weight loss, are now prohibited from doing so. They have till April or May to transition to branded injectable versions. This affects the bottom line of all these telemedicine prescribers such as Ro, Weight Watchers, Future Health (a heavy local radio advertiser), 23andMe, and Hims & Hers. Hims, the showiest in class, took a breathtaking 25% hit on their stock between Friday and Monday.

It is not only cost of branded drugs but also that so many competitors have jumped into the field, creating another shortage of the branded drugs, that looms. Suppliers of compounded drugs, the high volume compounding pharmacies (not your corner pharmacy that does compounding based on Rx), may be reluctant to continue supplying telemedicine prescribers in reasonable fear of FDA action or pharma lawsuits that could put them out of business.

Hims also publicly took the hardest line against the pharma companies, implying in their now infamous Super Bowl commercial that their obesity drugs are priced “for profits, not patients”, unlike Hims’, of course. Novo Nordisk, the Ozempic and Wegovy manufacturer, in turn has taken a hard stance against the compounders pointing out that a compounded version isn’t standardized nor FDA-approved for safety and efficacy.

A custom, compounded version of a drug can only be sold when there is a shortage or if the branded drug is in some way inappropriate for the patient requiring a customized version, e.g. with adjusted dosage, method of dosing, or added/deleted ingredients. Look for Hims and other telemedicine prescribers to start pushing this POV. FierceHealthcare, MedCity News

Some FDA reviewers reinstated after DOGE cuts. The ~230 probationary and other employees who were let go with severance then partially reinstated are reported to be reviewers in the CDRH (Center for Devices and Radiological Health). The 183 reinstated reviewers are actually funded by the industry through the Medical Device User Fee Amendment (MDUFA) agreements to help speed the review and approval process. There is considerable confusion about this because phone calls went out over the weekend but as of today (Monday) there is no written confirmation from HR or the Office of Personnel Management (OPM). It remains murky as do layoffs in the rest of HHS. FierceHealthcare, Endpoints

Veradigm changes up, expands its board in agreement with major investor; adds directors, chair to step down

February 22, 2025 | by

A new sheriff at Veradigm? A stiffly written press release from Veradigm announced Big Changes to its board of directors–and an agreement with a major shareholder, Kent Lake PR LLC. The cooperation agreement with Kent Lake adds four independent directors, two effective on 20 February and two to be named later subject to Kent Lake’s approval. The two immediate additions are Vinit Asar and Louis Silverman. Mr. Asar is the former CEO, now executive chairman of Hanger, Inc., a medical services provider. Mr. Silverman is CEO of Hicuity Health, which provides telemedicine services to high-acuity care settings. 

Current long-time chairman Greg Garrison will retire following the filing of the 2022 Form 10-K, expected shortly. Board member Jonathan Judge, previously CEO of Paychex and on the board for nearly nine years, stepped down on 14 February. He was chair of the nominating and corporate governance committees, according to his listing on the Veradigm website (still up). Board member and audit committee chair Beth Altman previously resigned on 28 January for stated health reasons.

In January, Veradigm announced that efforts to sell, which looked promising at the end of 2024, had failed to sell the whole company or assets and that the board was examining, with an unnamed strategic advisory firm, a standalone future [TTA 31 January]. According to the current release, the current board asked for shareholder input regarding board composition and ‘refreshment’. Reading between the lines of the release, it was both an agreement and a settlement of some kind with Kent Lake, a major shareholder of Veradigm, and the only one mentioned. Kent Lake PR reportedly owns 3% and Kent Lake Capital an additional 3%. Both are based in Puerto Rico. The release prominently features a statement by Benjamin Natter, managing member of Kent Lake Capital, on how changes to the board will promote delivering value to customers and the healthcare system while also generating “attractive returns to shareholders”. Veradigm is currently valued at $527 million. 

Also stated in the release is that new members will add “deep strategic planning, finance, healthcare and restatement experience.” Interestingly, Vinit Asar is also experienced in the latter, having steered Hanger through a financial restatement and NYSE delisting process. In this case, Veradigm is concentrating on becoming  current with its financial statements from 2022 in order to get relisted on Nasdaq.

It is clear that one major shareholder decided to go Full Activist and force changes at Veradigm after the possibility of a sale evaporated like a snowball in July. Reuters

The wrapup line on ViVE

February 22, 2025 | by

Digital health conference ViVE 2025 in Nashville wrapped on Wednesday–and surprisingly, there weren’t any bombshells. The well-attended Sunday-Wednesday conference in the Music City was abbreviated due to…snow. Even though the snow came in at a less-than-forecast 1.5 inches, many participants, concerned about flights, headed for home.

Observations from an (anonymous) attendee on HIStalk (News 2/19/25 and 2/21/25) were generally positive. He or she reported a filled conference, show floor, and meeting spaces at the Nashville Convention Center and much more. Highlights:

  • 10,000 attendees–2,500 more than ViVE 2023 in Nashville, and 2,000 more than 2024 in Los Angeles. 30% were C–level from 725 provider and payer organizations represented. Tuesday was the busiest day but only 2,000 remained on Wednesday due to the snow report.
  • The real action took place in 1:1 and group meetings, most pre-scheduled–over 5,000 were booked in ViVE’s meeting spaces and “cubes”. The Provider and Payer Connect Lounge was much larger with at least 170 small tables for meetings with vendors. Unsurprisingly, the Investor Connect Lounge was smaller. The impression this person had was that there were fewer investors attending this year.
  • The show floor had a lot of activity and was nearly filled. Effectively every vendor pitched their AI capabilities. By the last day, usually the lightest anyway but with the snow, one-third were unattended or packed up. 
  • Sparsely attended and in smaller spaces: the four primary presentation stages.

ViVE has become a place to meet, talk, initiate/advance the buyer journey, and move towards a ‘deal deal’. It’s also for scoping out the competition. Presentations and panels have become beside the point.

A third article in HIStalk’s Readers Write were additional reflections from Mike Silverstein, a managing partner at DRI (Direct Recruiter Inc.), recruiting in the health IT and life sciences area. AI tools “are really getting smart, borderline scary smart”–especially AI agents being trained on “serious healthcare data and workflows”. Vendors are layering their workflows on top of off-the-shelf AI agents and the speed to market is “blinding”. Investment is up too with less ‘hand to mouth.’

Announcements, heavy on the AI, made during ViVE and recapped in MedCity News: 

  • Data analytics firm MultiPlan rebranded as Claritev. The company provides payments and pricing solutions based on healthcare claims data. It will start trading on the NYSE under CTEV next Friday 28 February. Release
  • Abridge announced their $250 million Series D [TTA 21 Feb]
  • Automation platform developer Innovaccer announced seven new AI agents. These ‘agents of care’ automate administrative  tasks in scheduling, protocol intake, referrals, prior authorizations, care gap, HCC, and patient access. The agents are designed to support multiple care teams, including clinicians, care managers, risk coders, patient navigators, and call center agents. Release
  • Lumeris launched an AI tool, Tom, that automates tasks like care coordination, chronic disease management and patient outreach in clinical workflows for primary care providers. Release
  • UPMC Enterprises soft-launched a virtual environment, Ahavi, for developers to test and evaluate the efficacy of AI models against UPMC’s patient population data. UPMC Enterprises is the innovation and commercialization arm of the UPMC health system. More on this from HealthPoint and FierceHealthcare.
  • IKS Health launched a generative AI scribe, Scribble Now. It automates notes during the patient visit via automated speech recognition (ASR) and generative AI (GenAI). Release
  • Healthcare operations software developer Symplyr launched the Symplr Operations Platform (SOP). It unifies separate solutions onto a AWS cloud-based infrastructure to unify disparate solutions. Release

Breaking: Will telehealth extensions survive past 31 March? ATA addresses rumors.

February 21, 2025 | by

The answer is “we’re working on it”. As Readers recall from the blur that the final Federal budget extension turned out to be, cut down from an elephantine 1,547 pages to 118 pages, three telehealth provisions from the American Relief Act (ARA), of a total of six in the elephant version, were approved through 31 March [TTA 19 Dec]:

  • The Special Diabetes Program (Sec. 3102)
  • Telehealth flexibilities (Sec. 3207)
  • Hospital care at home (Sec. 3208)

A more extensive explanation of the above three that were extended, and the provisions that were omitted, is available here from law firm McDermott Will & Emery.

The American Telemedicine Association‘s advocacy arm, ATA Action, has sent out an email to media rebutting current rumors that the telehealth flexibilities will not be extended. They affirm that President Trump and his team are working with Congress to extend telehealth flexibilities. Since there is no link as of yet on ATA’s site, your Editor is doing what she never does, which is to print a release verbatim deleting only the ‘about’ section–because of its importance. The ATA release as PDF:

ATA ACTION ADDRESSES RUMORS REGARDING TELEHEALTH EXTENSIONS

 WASHINGTON, D.C., FEBRUARY 21, 2025 – ATA Action, the advocacy arm of the American Telemedicine Association, addressed today’s rumors, mistakenly claiming that telehealth services will not be extended past the March 31 deadline.

“Despite today’s rumors, our conversations on Capitol Hill confirm that President Trump and his team are actively working with Congress to extend vital telehealth flexibilities beyond the looming March 31, 2025, deadline,” said Kyle Zebley, senior vice president, public policy, the ATA and executive director, ATA Action. “Telehealth is a bipartisan success story, delivering affordable, safe, and effective care to millions of Medicare beneficiaries. In 2020, the Trump administration acted swiftly to expand telehealth access, a move that has since enjoyed broad support across Congress and the Biden administration. Telehealth must always remain a bipartisan issue.

“We commend both Administrations and Congress for their leadership and urge them to make telehealth flexibilities permanent or extend them for as long as possible. Medicare beneficiaries deserve access to care that is convenient, effective, and uninterrupted,” Zebley added. “Patients, providers, and policymakers across the aisle recognize its value, and ATA Action remains committed to preserving and strengthening this support. We stand ready to work with all lawmakers and the administration to keep telehealth accessible and ensure it remains a cornerstone of modern healthcare. We cannot afford to let access to telehealth expire on April 1.”

The next few weeks will tell, now that RFK, Jr. is now confirmed at HHS. And Congress will be pressed to address not only the budget, but also the scorching hot button of extending previous tax cuts to help jumpstart the economy.

News roundup 21 Feb: UHG offers buyouts to 30K before layoffs (updated); more inside the Transcarent-Accolade deal; Hims acquires NJ testing company; layoffs bite inside HHS; in fundings, Vitalchat gains $6M, Frontera seeds at $32M, Harrison.ai $112M (AU), Abridge’s $250M

February 21, 2025 | by

UnitedHealth Group ends an annus horribilis with more horribilis. UHG offered early this week 30,000 employees their “Voluntary Resignation Severance Program” or VSRP. If the employee accepts between 24 February and 3 March, the program offers anywhere from 7 to 30 weeks severance, based upon tenure and salary grade; they’ll receive their termination date on 17 March with all released by 1 May, as of now. A wrinkle: their managers must approve of their taking the package, which could set up a situation of being released later involuntarily. UHG has 420,000 employees and oddly, is still posting available positions but they may be ‘ghost’.

Reports have been compiled by employees posting largely anonymously across social media and websites such as Reddit, Facebook, LinkedIn, TikTok, and TheLayoff.com. The buyout offer, according to reports, is concentrated in the benefits operations area. According to CNBC’s sources, benefits oversees multiple subdivisions that help manage customer service, claims, enrollment, customers’ insurance benefits, and more. As is typical with voluntary severance offers, the whip is that if employees do not take the VSRP, those laid off later will receive a reduced package.  There is no information about additional benefits, such as 401(k) and incentive vesting, or healthcare benefits–the last ironic for a healthcare company.

On social media, the betting is that UHG is only the first payer to institute layoffs, with the decline in Medicare Advantage payouts and reductions in ACA subsidies. Other factors: AI (per the last earnings call, they are replacing many customer service functions with AI programs) and offshoring. This is not going to be a great year for any payer, if you work for one, and their suppliers/partners. HealthPayerSpecialist (hat tip to Mansur Shaheen via LinkedIn), FierceHealthcare, PYMNTS.com, Minneapolis Star-Tribune   A followup article by Mr. Shaheen with UHG interviewing employees and accessing company information is here. Another reason why is that UHG’s attrition rate, for various reasons including company response to the Brian Thompson murder and their higher pay rates, was much lower than forecast.

Updates on the Transcarent deal for Accolade. Contained in the latter’s SEC Schedule 14A, an announcement of a stockholder meeting (virtual) and preliminary proxy statement, are more tidbits in the runup to the deal with Transcarent:

  • Transcarent’s merger sub was formed on 3 January, indicating this deal has been on the table for some time
  • In April 2024, Accolade was considering acquiring a strategic company (unnamed). That company rejected the offer and instead offered to buy Accolade by May. Later that month into August, a special committee and outside advisors considered competing purchase offers, well over 16.
  • Transcarent’s original offer was made at end of July, was unsolicited, and an August proposal was rejected. A second proposal was rejected in September based on financing.
  • In October, after business reverses, Transcarent submitted another bid for shares at $7.25 and was delayed by the special committee 
  • Between that date and year’s end, the other proposals faded away for a variety of reasons.
  • Transcarent’s final offer was $7.03 per share and accepted in January.

Regarding transitioning incentives in the deal, expected to close in Q2:

  • It can be terminated by 7 October. If Accolade terminates it, the payment to Transcarent is $19.8 million. If Transcarent terminates, the fee to Accolade is $29,950,000
  • Top management (Rajeev Singh, Stephen Barnes, Robert Cavanaugh, and Richard Eskew) shares will accelerate in vesting. Some top management such as CEO Singh will enjoy retention bonuses.
  • It describes treatment of employee benefits such as restricted and performance stock units (RSU, PSU) being converted to cash and that other benefits for continuing employees will be cut over for a year.

Also Endpoints News

Hims & Hers buys a testing lab in NJ.  The acquisition of Sigmund NJ LLC, also known as Trybe Labs, in Kearny NJ will support at-home blood draws and more complete and affordable whole-body testing. The acquisition was self-financed and not disclosed. Hims, a telehealth prescriber for GLP-1, ED, hair loss, migraines, and anti-depressants, in the release pointed out that the Trybe Labs buy will enable them to serve high-impact clinical categories including low testosterone, perimenopausal, and menopausal support for patients and providers. Through using a blood lancet, they will test for hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. Mobihealthnews, Endpoints News

Layoffs within HHS are extensive–and as of a court action today, going through. Most of those eliminated by DOGE (Department of Government Efficiency) are probationary hires–in their first year–and some in year two. Those released at HHS include 1,300 at the Centers for Disease Control and the National Institute of Health (unknown but expected to be upwards of 600). Those released will have a month’s severance but will end work on Friday 14 February. Some probationary NIH employees will be retained. Cuts include CDC and other HHS contract workers and include dozens at the Vaccine Research Center housed at NIH. The current acting principal deputy director, Nirav Shah, will be departing on 28 February as will Renee Wegrzyn, the appointed head of Advanced Research Projects Agency for Health (ARPA-H), which performs biomedical research in conjunction with the private sector established in 2022 by the last administration. Ironically, reviewers of Elon Musk’s Neuralink project and other brain-computer interface companies were among the 20 fired at FDA’s Office of Neurological and Physical Medicine Devices.

HHS employs more than 80,000 people across multiple agencies and has a budget of $1.8 trillion. NIH alone has 20,000 people and has a $47 billion annual budget. STAT, Mobihealthnews

Funding highlights include a stunning seed round:

  • Vitalchat, a provider of in-patient virtual nursing and procedural telehealth, closed a $6 million Series A round. Investors were led by Green Harvest Capital Industries (GHC Industries). Two of their principals will join the Vitalchat board: Ankit Patel, GHC’s CEO, and Saagar Parikh, co-founder/principal. The new funds will be used for product innovation, market expansion, and deeper AI integration into clinical workflows for its AI-assisted virtual sitters. Release
  • Frontera Health’s seed round of $32 million was a return to 2020’s Big Raises. It was co-led by Lux Capital and Lightspeed Venture Partners, with Bison Ventures, Menlo Ventures, and Inspired Capital participating. Frontera specializes in autism services, including virtual autism diagnosis and assessments, as well as in-home and center-based ABA therapy. It uses what they call ‘digital phenotyping’ to analyze interactions and behaviors, providing real-time cognitive reasoning and objective data points for clinical assessments. Behavioral Health Business noted substantial raises by other companies such as Anna Health and Prosper Health, along with private equity (PE) investments.  Release, Mobihealthnews
  • Down Under, Harrison.ai’s Series C totaled $112 million in a Series C funding. It was led by Aware Super, ECP, and Horizons Ventures. It provides medical imaging diagnostic support in radiology and pathology, including workflow solutions. Harrison is opening a US headquarters in Boston to expand their US business. It already has clients in APAC, EMEA, UK, and US, where it has 12 FDA clearances. One of their CT brain algorithms has FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP).   Release, Mobihealthnews
  • Abridge raised an old-school level $250 million Series D investment. This was co-led by Elad Gil and IVP, with a long list of participants including Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures (NVIDIA’s venture capital arm), Redpoint Ventures, Spark Capital, and SV Angel. Abridge’s platform converts patient/clinician conversations into structured clinical notes in real time using (guess) generative AI. Funding will be used to further develop AI capabilities and commercial growth to support broader applications. It claims 100 of the largest and most complex healthcare systems in the US, from rural systems to children’s hospitals, leading academic systems, and nationally recognized cancer centers, Release

“It’s alive!” Walgreens’ deal with Sycamore Partners may be back on the table: report

February 19, 2025 | by

Resuscitated, according to Tuesday reports. CNBC’s David Faber, currently co-anchor of CNBC’s morning “Squawk on the Street”, said Tuesday (yesterday) that the take-private deal of Walgreens Boots Alliance by Sycamore Partners and possibly other entities, has gone from “dead” to “alive” in his books.

The Walgreens deal was reported, but called “rumors and speculation” by Walgreens in December right before the Christmas blackout [TTA 10 Dec 2024, 8 Jan]. It withered like sycamores do in a cold 2025 winter, when Walgreens piled up Heaping Helpings of Misery in the following weeks: January FY25 results, suspending its dividend, and arbitration awards, civil settlements, and penalties.

Yet…a little-noted report local to Chicago noted that as of January’s end, Sycamore had been approaching private credit firms trying to put together debt financing for a deal. Whether this was for WBA or another deal is unknown. But Sycamore is no newcomer to this. Crain’s Chicago Business

There isn’t much (right now) beyond Mr. Faber’s call in the news coverage, and certainly no comments by either WBA or Sycamore. But his show and his persona–a 30+ year veteran of CNBC known for his insider savvy and calls–are influential enough to drive the stock up a dollar from $9.70 to $10.98 on Tuesday. The price lingers on through today at $10.86.

What also lingers? The sheer difficulty of Sycamore pulling off a complicated and pricey deal with WBA. It is not one of the VC elite with a ton of money from limited partners aching to invest. But what it has is a track record in putting together complex deals and saving debt-ridden retailers before, notably with Staples in 2017 and more recently Chicos FAS and Playa Bowls. Its focus is retail and e-commerce, making it an odd (but not too odd) partner for Walgreens. It might be interested in kicking up a downsized retail operation and in Boots’ thriving retail/e-commerce business in the UK, leaving the healthcare/VillageMD, pharmacy, and PBM ownership to others. It’s led to speculation that their interest might be a cherry-pick as part of a breakup team. But, as mariners know, the wise sailor knows that it’s any port in a storm.  Crain’s Chicago Business, Yahoo! Business

Two Must Reads: What’s Glen Tullman’s real game with Transcarent and the Accolade buy? (updated) Plus an extra helping on the VC ‘mafia’ and Hippocratic AI.

February 19, 2025 | by

Make some time over the morning cuppa or lunch for a brilliant investigative report on Transcarent and Glen Tullman. Arundhati Parmar over at MedCity News pulls aside some of those Great Oz curtains, surveys the scene, then asks the questions that few have dared to. Such as:

  • Is Transcarent’s model not working? Are they successful or not?
  • Or are those corporations and benefits consultants so hidebound, so powerful, so exclusive, that they forced Glen Tullman to buy into the traditional care navigation model–and he is a Victim of the System?

Those of us in the healthtech/digital health industry have looked with amazement, mixed with dismay, at Mr. Tullman. The amazement is the powerful voice he has among us, reinforced by his investment funds. The dismay comes from the $18 billion sale of Livongo to Teladoc in the palmy days of 2020. As we reported, even then it was regarded as a dubious move. It then became a case study in What Not To Buy–Or Do. From Mr. Tullman’s and his management’s perspective, Teladoc’s offer proved to be Grand Theft Auto. In other words, a heist to end all heists. For Teladoc, it was a disaster. Mr. Gorevic, as we know, is gone and Teladoc is rebuilding. In many ways, Teladoc has never recovered and may never. 

Mr. Tullman, who founded two VCs, 7wireVentures and most recently 62 Ventures, after selling Livongo almost at once founded Transcarent with a vision that it would do the job through software that human corporate care navigators and benefits consultants couldn’t do–take out all these middlemen and deliver to both companies and their employees better quality healthcare at a much lower cost. It would also turn the PMPM (per member per month) pricing scheme into a risk-sharing model based on use. He made the rounds at every conference pitching against traditional care navigators, including the most prominent, Accolade.

Last month, he and Transcarent made a substantial offer to buy, yes, Accolade, for $621 million [TTA 8 Jan]. Publicly traded and struggling for years, recently losing major accounts, Accolade was on the block–yet its model is so different than Transcarent’s that it feels like double vision. In fact, this deal had been in the works since last July–initiated by Glen Tullman. Why?

A clue from one of Ms. Parmar’s sources, most of whom have had to be anonymous for obvious reasons:

“He is an amazing storyteller and amateur magician. But like any story and magic trick, sometimes it’s hard to tell what is real and the trick doesn’t work. ”

Ms. Parmar’s path to answering these questions is top notch, and this Editor invites you to read it, start to finish–and return to it again. When you finish it, you’ll not only know about Transcarent’s current business realities, but also learn a great deal about how companies regard care navigation plus the economics. The discrepancy, as always, is between the ‘vision’ and reality. Is he in it for the mission, or has reality bitten? Is Glen Tullman a Hypocrite or a Victim of the System He Aimed to Disrupt? (I also want to commend MedCity News for publishing this)

Update: See Ms. Parmar’s video on LinkedIn regarding the response to her article. Of note: 1) the complete lack of response from Transcarent’s corporate communications team*. 2) If you want investigative journalism, you have to be willing to be a source, so when you see something wrong, you have to reach out. That means risk. (*No surprise to this Editor, who directly contacted Transcarent’s corporate comms team to clarify whether 98point6’s telehealth service, purchased for $100 million, still was operating–no reply to this simple ‘layup’. TTA 5 Feb)

Our ‘extra of the day’ is from AI Health Uncut. Sergei Polevikov, publishing on Substack, puts on the scuba gear and dives deep not only into Hippocratic AI, which promotes AI agents for various types of healthcare contact requirements, but also its key funder, General Catalyst and its head, Hemant Taneja. For starters: Hippocratic AI is the most expensive AI company on Planet Earth if viewed as valuation x revenue multiple. Mr. P brings the numbers and the heat.

If you’ve looked at fundings in the past two years, versus the ‘olden days’, and wonder why the same names always seem to pop up, it is because VC fundings have become concentrated among very few companies. As this Editor noted in the Rock Health 2024 results, of 391 VC funds, 30 raised 75% of all US committed capital. Nine of those funds accounted for 50% (Pitchbook). Sitting at or near the top is General Catalyst, which has moved into wealth management and through HATco, owning hospitals such as Summa Health. But there are other reasons as well, and Mr. Polevikov gets into the murk.  It’s another one for a long cuppa or lunch. And it is part one of two, upcoming!

I encourage our Readers to support Sergei’s work on Substack–for a modest annual subscription amount, you gain full access to his work, past and present, charts, videos, and articles. (I did, and have noted his site among Websites We Like.) The link above may be paywalled as a result for non-subscribers. [Disclaimer: through commenting in this article, I pointed out GC’s move into GC Wealth, and my short news item is linked.] He also recently posted a lively panel discussion video with Alex Koshykov, Matthew Holt, and James Wang.  

2025 is proving to be a year of massive change in healthcare. It may be a year of comeuppance for those we’ve regarded as all powerful and fearsome. Yes, the cliché ‘sunshine is the best disinfectant’ is true, but a good dose of hydrogen peroxide, boric acid, or Lysol helps.

News roundup 2: RFK Jr. confirmed as HHS Secretary, new MAHA commission formed; Amwell narrows loss by 68%; HEALWELL (CA) nears close of Orion Health (NZ) buy; Summer Health buys Caraway; Spectrum.Life (IE) plans to double users; 2025 NY Digital Health 100 announced

February 14, 2025 | by

Robert F. Kennedy, Jr. was confirmed this morning as US Health and Human Services (HHS) Secretary. The Senate vote was fairly standard for President Trump’s appointees, along party lines (with one exception) in a 52-48 vote. Secretary Kennedy survived bare-knuckle committee hearings (and a family ‘diss’ from cousins) to put into place measures to Make America Healthy Again (MAHA) as promised during the 2024 presidential campaign. Today’s presidential Executive Order also makes Secretary Kennedy the leader of the MAHA Committee, which, according to a White House statement will be “tasked with investigating and addressing the root causes of America’s escalating health crisis, with an initial focus on childhood chronic diseases.” such as autism and fatty liver disease, plus adult asthma and the causes of the low US life expectancy.  The EO’s four policy directives focus on reversing chronic disease through:

  1. transparency on health data to “avoid conflicts of interest in all federally funded health research
  2. prioritizing “gold-standard research on why Americans are getting sick” in all federally-funded health research
  3. working with farmers to ensure food is healthy as well as affordable
  4. expanding health coverage and treatment options “for beneficial lifestyle changes and disease prevention.”

The timeframe is short: 100 days to produce an initial assessment, and 180 days to produce a strategy to improve child health. All this and learn HHS too. Next up in hearings: Mehmet Oz, MD as CMS Administrator, expected to face far less flak.  FoxNewsDigital

Amwell straining to get weller, financially. Still in the red but improving by about 68%, Amwell’s full year 2024 net loss was $212.6 million on $254 million in revenue versus 2023’s net loss of $679.2 million, which included a non-cash goodwill impairment charges of $436.5 million. Taking away the one-time charge though, the loss improvement was $31 million.

Q4 had a strong 36% improvement in subscription revenue versus prior year, driven by the implementation of a 22-month joint contract with technology firm Leidos to digitize the Military Health System (MHS). However, this contract expires in July and given cost-cutting in Washington, is not assured of renewal. Leidos is already in negotiation with the Department of Defense for a three-year extension. In cost reduction, Amwell reduced R&D expenses by 29% and looks at further cuts for 2025 of 10%.

For 2025, Amwell forecasts revenue in the range of $250 to $260 million, including the previously announced divestiture of Amwell
Psychiatric Care, about $30 million) with adjusted EBITDA loss between $55 to $45 million. Positive cash flow is not forecast until 2026. But Amwell’s share price, in such a hole that the NYSE threatened delisting a year ago, has bounced from below $8 in January to closing at $11.73 today (13 February).  Amwell 2024 financial report, Healthcare Dive

HEALWELL AI one step closer to closing its purchase of Orion Health. HEALWELL needed consent from New Zealand’s Overseas Investment Office of New Zealand (OIO) to proceed with the purchase announced in December [TTA 19 Dec 2024]. HEALWELL is an artificial intelligence company focused on preventative care through the early identification and detection of disease while Orion’s products–Orchestral, Amadeus, and Virtuoso–are data exchange, patient record, and analytics platforms that benefit clinicians and patients. The complex buy totaled NZ$200 million/CA$165 million (US$115 million) for 100% of Orion’s private shares. CA$86 million will be paid in cash and the balance will be paid in HEALWELL stock plus CA$20.5 million in a 3-year performance-based arrangement. The companies are now on track to complete the sale by 1 April. Newsfile release

Summer Health buys Caraway. Summer is a text service that connects parents with pediatricians for urgent care through texting and converts doctor’s and clinical notes into lay language via generative AI. Caraway served a different market–Generation Z women between 18-29 for mental and reproductive health. What they did share was one investor: the powerful 7Wire Ventures. Was this another Shotgun Merger? While Caraway enjoyed an initial funding of over $10 million plus $16 million during the 2023 slump, apparently it had ceased business in December and took its website offline. How Summer positions it is that it now can serve children, teens, and young adults. In addition to its 50-state DTC direct pay service, it will pick up Caraway’s insurance contracts. There are no references to purchase price or workforce transitions. Other than the release, there’s no reference to Caraway services on the Summer website. Summer had a Series A raise of $11 million last April.    Summer release, Behavioral Health Business  Hat tip to Mario Aguilar of STAT Health Tech’s newsletter.

Following up on Ireland’s Spectrum.Life.  They ended their 2024 serving 1.5 million users and project 3 million in 2025 in Ireland and the UK. Spectrum.Life now has 300 employees in Dublin and Manchester delivering digital health, mental health, and wellbeing for employers and employees in the workplace, insurers, and educators. Last year it was listed as #41st in Deloitte Ireland’s 2024 Technology Fast 50 Awards. Release.

And a bit closer to the Editor’s home is the latest New York Digital Health 100. Named by Digital Health New York (DHNY) and in its sixth year (oh, the changes!), the list has 48 new startups (which is illustrative of the churn in the NY digital health scene) these 100 companies raised about $4 billion, with over half going to biotech (26%), care delivery (24%), and mental health (13%) companies. A download of the full report and lists is available at the above link.

News roundup: PSI awarded $156M contract for VA EHR testing; $50M for Fay nutrition; General Catalyst’s wealth management expansion; UniDoc’s HealthCube debuts in Ukraine

February 13, 2025 | by

VA awards Planned Systems International a potential five-year, $156.1 million contract to support the VA’s EHRM (Electronic Health Record Modernization). The Independent Enterprise Testing and Support Services (IETSS) contract supports the EHRM-IO (Integration Office) team that is restarting the transition from VistA to the Oracle Cerner EHR. PSI will test and evaluate software, infrastructure, and environments, plus the operations of the independent verification and validation test center and test center environments hosted in VA Enterprise Cloud. It covers PSI’s project management, test and evaluation support, testing and technology support, test systems engineering and implementation support, and test process and quality management support. The five-year contract, as is typical with Federal contracts, is for an initial year then renewable for four 12-month terms. Another confirmation that EHRM-IO is moving forward on their plan announced before Christmas 2024, when the VA formally stated that they were planning for deployment in four Michigan facilities — Ann Arbor, Battle Creek, Detroit, and Saginaw–for implementation by mid-2016 [TTA 8 Jan]. GovConWire

Food as medicine is catching on. San Francisco-based Fay has scored a $50 million Series B round, led by Goldman Sachs with participation from previous investors General Catalyst and Forerunner, bringing their investment since 2024 to $75 million. The fresh funding will pay for growth and network expansion. They are claiming a valuation of $500 million.

Fay at present has a network covering most states of 2,300 registered dietitians (RDs) that integrate through Fay’s platform with major payers including United Healthcare, Aetna CVS Health, Blue Cross, Anthem, Cigna, Optum, and Humana, plus large employers such as Amazon, Microsoft, and Pepsi. The RDs provide personalized, in-person or virtual nutrition and lifestyle counseling to members or employees at little to no cost, while the platform automates processes such as insurance claims, scheduling, and patient follow-ups for the RDs. In addition, Fay can help RDs build their private practice and get credentialed with insurance. Over half of Americans struggle with diet-related chronic conditions (Frontiers in Public Health). Fay is in an especially sweet spot, as nutrition and quality of food, with the pending confirmation of Robert F. Kennedy, Jr. as HHS Secretary, is front and center. Release, MedCityNews

Speaking of General Catalyst, they are expanding beyond being one of the few dominant venture capital groups in a consolidating investment sector by expanding GC Wealth into a wealth management firm for entrepreneurs and others who have Struck It Rich (or have the potential to) in hot sectors such as AI. Running it out of San Francisco (where else?) is Dave Breslin, a former First Republic Bank executive who headed their private wealth unit. He recently hired several First Republic alums based out of Boston. According to the BBJ, it now has $2.3 billion in assets under management–and clients were invited last year to invest in General Catalyst’s seventh fund.  Founders should think long and hard about having your funder also manage your personal wealth–so it seems to this Editor. Boston Business Journal. Axios previously reported that General Catalyst is quietly exploring selling a share in its holding company. It currently has $32 billion in assets.

The ‘doc-in-a-box’ idea now has a fresh life in very specific uses. Canada’s UniDoc Health’s H3 Health Cubes have some interesting placements with the Italian Government to serve rural areas as a remote virtual clinic in locations such as the Municipality of Aliano’s Territorial Health Center. Also in Italy, the Aiutamoli a Vivere Foundation aid organization will place up to 15 units in Ukraine and the Gaza strip (though one suspects that events have eclipsed the latter placements).

For Ukraine, the H3 Health Cube funded by the Italian Agency for Development Cooperation (AICS), was delivered to a hospital in Yasinya in Ukraine scheduled to reopen on 14 February. It was received in mid-January by the Mayor of the City of Yasinia. along with additional aid such as food and hospital beds. It will connect doctors in that hospital, which treats wounded coming from the war zone as well as the local community, with Prof. Carlo Ventura’s team from I.N.B.B. of Bologna. Another Ukrainian hospital placement scheduled, in partnership with HP Inc., is for Okhmatdyt, Ukraine’s largest children’s hospital. A video of the HealthCube is on the UniDoc website.